Talent Pool

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Executive Appointments and Promotions

Pharma POOL Dr. Corey Goodman Dr. Martin Mackay Dr. Briggs Morrison Pfizer Announces Executive Changes Pfizer has launched an independent, stand-alone biotherapeutics and bioinnovation center under the direction of scientist and entrepreneur Corey Goodman, Ph.D., based in the San Francisco Bay area. Pfizer, New York, also has promoted Martin Mackay, Ph.D., to president of Pfizer Global Research and Development (PGRD), and appointed Briggs Morrison, M.D., as senior VP of clinical development in charge of the PGRD pipeline. Dr. Goodman cofounded two biotech companies, Exelixis and Renovis, and served as the CEO of Renovis. He received a B.S. in biology from Stanford University and a Ph.D. in neurobiology from the University of California, Berkeley. Dr. Mackay previously served as VP of Pfizer Global R&D and senior VP of worldwide development. He earned a first class honors degree in microbiology at Heriot-Watt University and a Ph.D. in molecular genetics at the University of Edinburgh. Dr. Morrison was most recently senior VP of research planning and integration at Merck Research Laboratories. He received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut School of Medicine. Nina E. Grove OneWorld Health Appoints VP The Institute for OneWorld Health, a nonprofit pharmaceutical company, has promoted Nina E. Grove, M.A., M.P.H, to VP for commercial planning and strategy. OneWorld Health’s mission is to develop safe, effective, and affordable medicines for people with neglected diseases of the developing world. Ms. Grove most recently was senior program director, malaria, for the San Francisco-based company. She earned a B.A. in biology from the University of California, Santa Cruz, and master’s degrees in medical microbiology and public health from the University of California, Berkeley. Dr. Robert J. Heine Lilly Expands Team of Experts Eli Lilly, Indianapolis, has appointed Robert J. Heine, M.D., Ph.D., F.R.C.P., executive medical director for the diabetes and endocrine division. Dr. Heine previously was professor of diabetology in the Department of Endocrinology and director of the Diabetes Centre at the VU (Vrije Universiteit) University Medical Center in Amsterdam, Netherlands. Dr. Jeremy Levin Bristol-Myers Squibb Adds to R&D Team Jeremy Levin, D.Phil., has joined Bristol-Myers Squibb as senior VP, external science, technology, and licensing. He reports to Dr. Elliott Sigal, chief scientific officer and president, R&D. Previously, Dr. Levin was global head of business development and strategic alliances at the Novartis Institutes of Biomedical Research. Dr. Levin received a B.A. (First Class Honors) in zoology, and an M.A. and D.Phil. in cell biology and chromatin structure from the University of Oxford, as well as a medical degree (MB BChir) from the University of Cambridge. Ross D. Pettit Ariad Hires VP, Clinical Operations Ross D. Pettit has joined Ariad Pharmaceuticals in the newly created position of VP, clinical operations. Based in Cambridge, Mass., Ariad discovers and develops breakthrough medicines that treat disease by regulating cell signaling with small molecules. Previously, Mr. Pettit was VP, clinical operations, at Coley Pharmaceuticals Group. He received his MBA from the University of Phoenix in Arizona and his B.Sc. from Kingston University in London. Bernard Poussot Wyeth Names New CEO Wyeth, Collegeville, Pa., has elected President Bernard Poussot as its new president and CEO. He succeeds Robert Essner, who remains chairman of Wyeth for an unspecified transitional period. During his 21-year career at Wyeth, Mr. Poussot has served as president of Wyeth-Ayerst International, president of the worldwide pharmaceutical business, and executive VP in charge of Wyeth R&D. He was promoted to president and vice chairman of Wyeth in April 2006, and assumed the additional role of Chief Operating Officer in January 2007. Biotech POOL Jack M. Anthony Dr. Philip Coggins Osprey Restructures Executive Leadership Osprey Pharmaceuticals has restructured its executive leadership, promoting Jack M. Anthony to CEO and appointing its current president and CEO, cofounder Philip Coggins, Ph.D., to the new position of chief scientific officer. Dr. Coggins continues as president of Osprey, a privately held biotechnology company developing leukocyte population modulators (LPMs) for serious, chronic diseases. Mr. Anthony, who most recently served as Osprey’s senior VP, corporate development, is based in San Francisco, where Osprey has located most of its administrative functions. Dr. Coggins remains in Montreal, where Osprey’s laboratory and R&D operations are based. Jonathan Klein-Evans Paul Williams Dr. Alexander A. Zukiwski MedImmune Announces Key Promotions and Hires MedImmune, Gaithersburg, Md., has made several new senior appointments across the organization as it transitions into its new role as the global biologics unit of AstraZeneca. Jonathan Klein-Evans, J.D., has been promoted to VP, intellectual property, overseeing all intellectual property issues for the company. He was previously director, intellectual property. Mr. Klein-Evans holds a B.A. in biochemistry from Columbia University, an M.S. in biological sciences from Stanford University, and a juris doctor degree from Georgetown University Law Center. Paul Williams was promoted to VP, sales operations, and is responsible for overseeing market research and marketing operations as well as for managing core sales operations competencies. Mr. Williams holds a B.S. in finance from Virginia Polytechnic Institute and State University. Alexander A. Zukiwski, M.D., has joined MedImmune as senior VP, clinical research, responsible for shaping and overseeing the company’s strategy for clinical trials. Dr. Zukiwski most recently served as VP, head of clinical oncology, for Johnson & Johnson Pharmaceutical Research & Development and Centocor’s oncology development group. He holds degrees in pharmacy and medicine from the University of Alberta and the University of Calgary. William T. Poncy New VP of Commercial Development at Accera Accera, Broomfield, Colo., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, has appointed William T. Poncy, MBA, as VP of commercial development. Mr. Poncy is responsible for directing the U.S. commercial launch of Ketasyn (AC-1202) as a medical food product for the treatment of Alzheimer’s disease, as well as lead development of Accera’s neurodegenerative disease franchise for ethical drugs now in development for Parkinson’s disease, Huntington’s disease, and age-associated memory impairment. Mr. Poncy was most recently VP of sales and marketing at Myogen, now Gilead Sciences. Chad M. Richards Transgenomic Appoints Head of Sales and Marketing Chad M. Richards has joined Transgenomic as senior VP of sales and marketing. Transgenomic, Omaha, Neb., provides products and services of automated high-sensitivity genetic variation and mutation analysis to the academic and medical research, clinical laboratory, and pharmaceutical markets. Previously, Mr. Richards was national sales director, cancer diagnostics division for Quest Diagnostics. Biopharmaceutical POOL Dr. Shahid Ali NeoPharm FortifiesR&D Staff NeoPharm, Waukegan, Ill., has promoted Dr. Shahid Ali to executive VP, R&D, responsible for developing a strategic plan for the biopharmaceutical company’s drug portfolio, which contains candidates for oncology and respiratory applications. Dr. Ali most recently served as VP of biological evaluations and R&D operations. Douglas N. Dobak Brian O’Callaghan NPS Makes Appointments NPS Pharmaceuticals has named Douglas N. Dobak as VP, regulatory affairs and drug safety. Mr. Dobak joins NPS from AstraZeneca where he most recently served as executive director, U.S. regulatory affairs, and global VP, regulatory affairs, respiratory, and inflammation area. Brian O’Callaghan has joined NPS as senior VP and chief commercial officer. NPS, Parsippany, N.J., discovers and develops small molecules and recombinant proteins, primarily for the treatment of metabolic, bone and mineral, and CNS disorders. Mr. O’Callaghan manages the company’s marketing and corporate and business development activities, including commercial development of NPS’s late-stage products and coordination of its joint-venture partnerships. Mr. O’Callaghan joins NPS from Covance, where he served as general manager of the cardiac safety and IVRS business units. He has an MBA from Henley College and a marketing degree from Cork Regional College/Marketing Institute of Ireland. Mark Erwin Adventrx Appoints VP of Commercialization Mark Erwin has joined Adventrx Pharmaceuticals in the new position of VP of commercialization, responsible for defining, developing, and leading the company’s commercial operations. Adventrx, San Diego, is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. Mr. Erwin previously served as senior director of program development for Centric Health Finance. He holds a degree in chemistry from Purdue University. Jim Fong Cell Therapeutics Names Senior Marketing Executive Cell Therapeutics (CTI), a Seattle-based biopharmaceutical company developing an integrated portfolio of oncology products, has appointed Jim Fong as VP, commercial operations. Mr. Fong is in charge of directing the sales and promotion of CTI products at the national and international levels, including product positioning, promotional programs, reimbursement strategies, and development and training of a national sales force. Previously, Mr. Fong was national sales director at CV Therapeutics. He holds a B.S. in psychology from UCLA. Dr. Sylvie Gregoire Shire Names Head of Human Genetic Therapies Business Shire, a specialty pharmaceutical company, has appointed Sylvie Gregoire, Pharm.D, as president of its human genetic therapies (HGT) business, charged with setting the strategic direction and managing pipeline growth at the unit. Dr. Gregoire is based at the Shire HGT headquarters in Cambridge, Mass. Dr. Gregoire most recently served as chairwoman of IDM Pharma. She received a pharmacy graduate degree from the Universite Laval in Quebec City, Canada, and a Pharm.D. from the State University of New York at Buffalo. Dr. Carl M. Mendel Synvista Selects CMO Synvista Therapeutics, Montvale, N.J., has named Carl M. Mendel, M.D., to the position of VP, clinical development and chief medical officer. Dr. Mendel was VP of metabolism projects at Sanofi-Aventis. He received a B.A. from Columbia University and an M.D. from the University of California, San Diego. Dr. Marc Rubin Titan Selects President and CEO Marc Rubin, M.D., has joined Titan Pharmaceuticals, South San Francisco, Calif., as president and CEO. Dr. Rubin succeeds Titan founder Dr. Louis R. Bucalo, who continues as chairman of the company. Dr. Rubin was formerly the head of global R&D for Bayer Schering Pharma. He received an M.D. from Cornell University Medical College. Dr. Ronit Simantov CuraGen Names VP of Medical Development Ronit Simantov, M.D., has joined CuraGen as VP of medical development. CuraGen, Branford, Conn., is a clinical-stage biopharmaceutical company focused on oncology. Dr. Simantov is responsible for leading the evaluation of data being generated from Curagen’s three clinical oncology programs, and supporting preparations to potentially transition one or more of these products into Phase III clinical trials during 2008. Previously, she was director, global clinical leader, oncology at Bayer Healthcare Pharmaceuticals. Dr. Simantov received a B.A. from Johns Hopkins University and an M.D. from New York University School of Medicine. Specialty POOL Dr. Richard Colonno Presidio Names New CSO Presidio Pharmaceuticals, a specialty pharmaceutical company focused on therapeutics for chronic viral infections, has named Richard Colonno, Ph.D., as chief scientific officer. Dr. Colonno is helping to lead Presidio’s efforts to identify new and promising drug candidates for HIV and viral hepatitis. Most recently, he held the post of VP, infection diseases drug discovery, at Bristol-Myers Squibb. He is a molecular virologist and holds a Ph.D. from the University of Kansas. Dr. Dennis H. Giesing New CSO at Urigen Urigen Pharmaceuticals, Burlingame, Calif., a specialty pharmaceutical company focusing on urological disorders, has promoted Dennis H. Giesing, Ph.D., to chief scientific officer. He has served as Urigen’s director of product development since January 2007. Dr. Giesing holds a B.S. in chemistry and Ph.D. in biochemical pharmacology from the University of Missouri. Dr. Stephen J. Peroutka Zogenix Appoints CMO Zogenix, a privately held neuroscience-focused specialty pharmaceutical company with offices in San Diego and Emeryville, Calif., has appointed Stephen J. Peroutka, M.D., Ph.D., chief medical officer. Dr. Peroutka, a neurologist and pharmacologist, most recently was the franchise development leader for pain at Johnson & Johnson. He received his M.D. and Ph.D. degrees from The Johns Hopkins University School of Medicine. CRO POOL Steve Albrecht Chiltern Names Director, Late-Phase Business Operations Global CRO Chiltern, Carlsbad, Calif., has appointed Steve Albrecht as director, business operations, late phase. He previously held an executive management position in late-phase development at Registrat. Phillip L. Banks Robert A. Stude Prologue Announces Senior Staff Additions Prologue, Columbus, Ohio, which offers a full range of clinical research services for Phase I-IV international and U.S.-based clinical trials in oncology and oncology-related studies, has promoted Phillip L. Banks to senior VP of biostatistics and data management. Mr. Banks, an M.S. statistician, is now responsible for overseeing the activities of the biostatistics, data management, and information technology departments. In addition, Robert A. Stude has joined Prologue as VP of clinical operations, responsible for overseeing the monitoring services, site services, and clinical services groups as well as interfacing with the project management and business development departments to ensure the quality, on-time progression of current studies and help secure new business opportunities for future trials. Mr. Stude most recently served as a senior director of monitoring and clinical services for Integrium Cardiovascular Research. Mary Briggs Dr. Ken Hintze Kendle Appoints New VPs Kendle, Cincinnati, has named Mary Briggs as VP, global sales, responsible for leading the company’s ongoing sales growth strategy, as well as developing the global sales organization. She joined Kendle in 2005 as senior director, strategic accounts. Kendle also has promoted Ken Hintze, Ph.D., to VP, global clinical safety and pharmacovigilance, from senior director, global clinical safety and pharmacovigilance. Dr. Hintze is heading up Kendle’s global clinical safety and pharmacovigilance business, including safety services in support of Phase I-IV trials as well as stand-alone safety projects. He earned a B.S. in chemistry from Iowa State University and M.S. and Ph.D. degrees in pharmacology/toxicology from the University of Iowa. David Provost INC Names Head of Late-Phase Services David Provost has joined the late-phase services team at INC Research as VP. Mr. Provost is responsible for managing the operational unit and providing strategic consulting to customers regarding the design and implementation of their global late-phase programs. Mr. Provost most recently served as senior executive director, post-approval strategic operations, for PPD. He has a bachelor’s degree in psychology from The Johns Hopkins University. Service POOL Cathy Betz Wolters Kluwer Creates Government Affairs Post Wolters Kluwer Health, Conshohocken, Pa., has appointed Cathy Betz to the newly established position of VP, government affairs, based in Washington, D.C. Wolters Kluwer provides information for professionals and students in medicine, nursing, allied health, pharmacy, and the pharmaceutical industry. With more than 20 years of legislative and government affairs experience, Ms. Betz is leading the implementation of a proactive stakeholder strategy to educate and inform federal and state legislators and other interest groups. Ms. Betz received a B.S. from James Madison University, a juris doctor from George Mason University’s School of Law, and a master’s in health administration from the Medical College of Virginia, Virginia Commonwealth University. Alan Birtchet Paul Mignon Jeffrey Thomas Dan Twibell inVentiv Health Creates New Teams inVentiv Commercial, an operating segment of inVentiv Health, has realigned its business into two divisions: inVentiv Strategy & Analytics and inVentiv Selling Solutions. As part of the reorganization, inVentiv has promoted Alan Birtchet to chief operating officer of Ventiv Sales Teams. Mr. Birtchet had been VP of commercialization for inVentiv. inVentiv has promoted Paul Mignon to president of inVentiv Selling Solutions and Jeffrey Thomas to president of inVentiv Strategy & Analytics. Mr. Mignon has overseen the inVentiv sales teams business since 2002. As president of inVentiv Selling Solutions, Mr. Mignon’s span of responsibility extends to business units that support the launch and operation of the sales teams, as well as the business development group. Mr. Thomas leads a group of inVentiv business units that provide clients with strategic planning, market analytics, research, market segmentation, and managed markets strategy. Mr. Thomas was previously VP and managing director of Ventiv Access Group, which he launched and managed and is now part of inVentiv Strategy & Analytics. Dan Twibell has been named chief client development officer in charge of inVentiv’s newly established client development and integration team. Mr. Twibell previously served as executive VP at CHS, an inVentiv company that provides outsourced marketing and commercialization solutions for healthcare clients. He leads a team responsible for working across inVentiv’s segments to build broad, multidisciplinary solutions for clients and develop tools and resources to support collaborative work. R. Kerry Clark Jeffrey W. Henderson Cardinal Health Makes Executive Changes Cardinal Health, a provider of products and services supporting the healthcare industry, has appointed President and CEO R. Kerry Clark to chairman and CEO. Mr. Clark succeeds Cardinal Health founder, Robert D. Walter, as chairman. Mr. Walter is serving as executive director of Cardinal Health, Dublin, Ohio, until his retirement in June 2008, after which he will remain on the company’s board. Mr. Clark received a bachelor of commerce (BCom) degree from Queen’s University. Cardinal Health has also appointed chief financial officer Jeffrey W. Henderson to the additional role of interim CEO of the company’s Healthcare Supply Chain Services (HSCS) sector following the resignation of Mark W. Parrish. Richard Zwickel Medi-Promotions Names Head of Medi-Scripts Plus Line Medi-Promotions has appointed Richard Zwickel as VP of Medi-Scripts Plus, the company’s next-generation prescription-pad model that includes patient offers from pharmaceutical manufacturers. Mr. Zwickel is responsible for the strategy and execution for all line extensions of the Medi-Scripts franchise, as well as key business initiatives related to the pharmaceutical clients for this legacy portfolio. He was previously national solution director for Thomson Healthcare’s PDR business unit. Mr. Zwickel received a B.S. in theoretical and applied sciences from Ramapo College, and has completed advanced coursework at Tuck Executive Education at Dartmouth College. Medical-Education POOL Steve Mandell Publicis Unit DIME Names Senior VP The Discovery Institute of Medical Education (DIME), part of the Publicis Healthcare Communications Group network, has appointed Steve Mandell senior VP, director of educational strategy and development. Mr. Mandell oversees DIME’s Chicago-based program teams, with primary responsibility for business development and strategic positioning. Mr. Mandell previously served as senior VP, sales and strategic projects, for CME LLC. Technology POOL Peter Benton Etrials Appoints COO Peter Benton has assumed the role of chief operating officer at Etrials Worldwide, Morrisville, N.C., a provider of e-clinical software and services to pharmaceutical, biotechnology, and medical device companies, as well as CROs. Mr. Benton, who has served as interim chief operating officer since July 2007, continues to be responsible for managing all of the company’s operations, with specific emphasis on service delivery and application development. He holds a bachelor’s degree in mechanical engineering from Northeastern University and an MBA in finance and strategy from the Wharton School at the University of Pennsylvania. Association POOL John M. Taylor III BIO Names Executive VP of Health The Biotechnology Industry Organization (BIO), Washington, D.C., has appointed John M. Taylor III as executive VP of health. Mr. Taylor most recently served as divisional VP for federal government affairs at Abbott Laboratories after a 15-year career with the FDA. He received a bachelor’s degree from Pennsylvania State University and a J.D. from the College of William and Mary. Agency POOL Leslie Bowes Dana Brousseau Alyce Erdekian Tim Glenn Aliza Hochbaum Lauren Marchitelli Mary Jo Marcontell Centron Expands Staff Centron, New York, a full-service medical communications agency and part of the HealthStar Communications network, has added several new staff members to its account teams. Leslie Bowes has been hired as an account executive. Previously, Ms. Bowes was a team support manager at Agency Rx. Dana Brousseau has joined Centron as an account supervisor. She most recently served as a senior account executive at Euro RSCG Life LM&P. Alyce Erdekian has assumed the role of VP, director of scientific services, a new strategic position within Centron. Previously, Ms. Erdekian was director of strategic publication planning. Tim Glenn has joined Centron as a creative supervisor from KPR, where he was a group art supervisor. Aliza Hochbaum has joined Centron as an account executive. Previously, she was an account coordinator at Euro RSCG Life Chelsea. Lauren Marchitelli has joined Centron as a VP, account supervisor. Previously, Ms. Marchitelli was an account supervisor at Harrison and Star. Mary Jo Marcontell has joined Centron as senior VP, group creative director. She most recently was an associate creative director at Euro RSCG Life MetaMax. Jane Parker New CEO Takes Helm at Interbrand Wood Jane Parker has joined global brand consultancy Interbrand Wood Healthcare as CEO. She is responsible for managing and building the business across the global network. Ms. Parker joins Interbrand Wood from Grey Healthcare, where she was president. Ms. Parker is based in New York and is responsible for managing and building the business across the global network. She succeeds founder David Wood, who steps into the role of chairman, where he is taking a more consultative role in the areas of new services, talent acquisition, and ongoing expansion into the entire spectrum of health-related industries. PharmaVOICE welcomes comments about this article. E-mail us at feedback@pharmavoice.com. January 2008

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK